Ask for a reprint
email :
2022
ACL
|
M.Dupleichs, C.Mellier, V.Montouillout, F.X.Lefevre, M.Limelette, S.Quillard, J.Y.Mevellec and P.Janvier, 'Controlled release of gallium maltolate complex from injectable phosphocalcic cements', Materials Research Express 9 (2022) doi:10.1088/2053-1591/ac8a3c
Some cancers have a tropism for bone: thyroid, breast, prostate, lung, and kidney cancer are the most common. Bone metastases can be treated by surgical resection and the resulting bone defects can be filled with injectable biomaterials. Among these, calcium phosphates may be biomaterials of choice due to their ability to locally release anti-cancer active ingredients. Herein we propose the synthesis of an injectable calcium phosphate cement (CPC) loaded with gallium maltolate (GaM). An extremely promising anti-cancer drug that also has antibiotic and anti-inflammatory properties. This synthesis was based on a commercial cement whose main component is -TCP (78 wt%) and the final product obtained after hardening is calcium-deficient apatite (CDA). Two formulations were prepared, containing 3.5% and 7% by mass of GaM. The pDRX, FTIR, and NMR MAS 31P analyses showed that the direct incorporation of GaM did not modify the final cement composition. Textural properties such as setting time, injectability, workability, and cohesiveness were well preserved or even improved. Finally, the mechanical strength, although slightly reduced, has remained perfectly compatible with surgical use. The structural integrity of the gallium complex in the CPC was confirmed by NMR MAS 71Ga. A Raman imaging study was used to visualize its diffusion within the cement during in vitro release experiments.
|
|
|